Latest CervoMed News & Updates

See the latest news and media coverage for CervoMed. We track all announcements, press releases, and industry mentions in real time, all in one place.

CervoMed

Clinical-stage biotechnology company developing treatments for age-related brain disorders

cervomed.com

Headquarters: Boston, United States
Founded year: 2023
Company type: Public company
Number of employees: 20–50

Last updated Today

Latest news about CervoMed

In short: CervoMed secured $10.5M in financing and aligned with the FDA on a Phase 3 trial design for its lead drug candidate, neflamapimod.

Company announcements

June 10 CervoMed

CervoMed announces private placement financing and partnering plan

The $10.5M raise extends runway to Q2 2027 and supports partnership to move neflamapimod into Phase 3 for DLB.

May 18 CervoMed

CervoMed reports Q1 2026 financial results and corporate updates

Cash at $12.9M, net loss $8.0M, and progress on Phase 3 DLB trial and other programs.

April 7 CervoMed

CervoMed announces neflamapimod update and panel participation

The update includes MRI analyses from Phase 2b, regulatory alignment, and finalized Phase 3 design. Additional data at AAN meeting.

March 12 CervoMed

CervoMed reports neflamapimod benefit in DLB without AD co-pathology

New analyses show greater clinical benefit in patients with lower pTau181 levels, supporting Phase 3 trial plans.

Media coverage

June 10 Yahoo Finance

CervoMed Announces Private Placement Financing and Plan to Focus on Strategic Partnering to Advance Neflamapimod into Phase 3 for Dementia with Lewy Bodies

Additional funding will extend anticipated runway into second quarter of 2027 Strategic priority is to establish a partnership to advance neflamapimod into Phase 3 in...

May 17 The Manila Times

CervoMed Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates

Reported positive Phase 2b RewinD-LB clinical data at CTAD 2025; additional analyses to be presented at AD/PD 2026 Obtained alignment with FDA and global regulators...

March 24 Yahoo Finance

CervoMed (CRVO)’s Q4 Results Feature Advancements in Its Neflamapimod Program for Dementia Lewy Bodies (DLB)

CervoMed Inc. (NASDAQ:CRVO) earns a place on our top 10 stocks under $5 that could triple. On March...

March 19 Seeking Alpha

CervoMed Announces Presentations at Upcoming AD/PD™ 2026 Scientific Conference

Data further support choice of patient population and dosing regimen in CervoMed's planned Phase 3 trial in dementia with Lewy bodies (DLB) DLB is the...

Never miss news about CervoMed

Track CervoMed and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

CervoMed competitors & trending companies

Browse news for competitors to CervoMed and other trending companies.